1. France Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Sanofi

Sanofi

SNW.DE
SanofiDE flagDeutsche Börse
75.53
EUR
+0.49
- -
90.80BMarket Cap
Sanofi
SNW.DE
(Deutsche Börse)

Recent

price

75.53

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
26.08
26.52
27.25
23.65
24.32
26.69
26.97
28.82
28.61
30.11
29.81
31.28
32.4
33.25
35.39
38.28
39.19
Revenue per Share
4.19
4.27
3.7
2.81
3.34
3.28
3.66
6.7
3.45
2.2
9.81
4.97
6.69
4.31
4.44
6.4
6.25
Basic EPS, GAAP
6.28
5.7
4.97
4.27
4.74
4.71
4.74
4.31
2.86
4.74
4.26
6.77
6.73
5.87
4.7
5.91
8.56
Free Cash Flow per Basic Share
2.4
1.04
2.64
2.75
2.79
2.83
2.92
2.95
3.03
3.07
3.14
3.2
3.33
3.56
3.76
3.91
- -
Dividend per Share
2.01
2.03
2.01
2
2.01
2
2.01
2
2
2.01
2.02
2.02
2.01
2.02
2.02
2
- -
Book Value per Share
6.8
-4.43
-0.59
3.4
1.92
5.07
5.1
3.89
-5.68
-1.44
-0.34
-0.34
2.89
0.5
9.46
3.4
3.36
Tangible Book Value per Share
1,305
1,322
1,320
1,323
1,316
1,306
1,287
1,257
1,247
1,250
1,254
1,252
1,252
1,252
1,251
1,220
1,208
Basic Weighted Avg Shares
34,036
35,058
35,957
31,291
31,999
34,861
34,696
36,221
35,677
37,631
37,369
39,175
40,561
41,618
44,286
46,716
47,354
Sales/Revenue/Turnover
24.94
21.76
21.92
20.32
21.06
20.46
21.69
19.88
17.53
19.07
21.11
23.35
26.94
20.88
20.15
20.54
19.84
Operating Margin (%)
5,129
5,553
4,907
5,095
3,280
4,276
3,301
3,686
4,279
7,445
3,671
3,351
3,108
4,429
3,586
5,678
1,912
Depreciation Expense
5,467
5,646
4,888
3,716
4,390
4,287
4,709
8,416
4,306
2,754
12,294
6,223
8,371
5,400
5,560
7,813
7,555
Net Income, GAAP
23.17
8.37
19.2
16.19
21.46
13.52
23.35
31.13
10.92
4.4
13.12
19.98
19.21
16.27
17.98
16.89
16.31
Effective Tax Rate (%)
16.06
16.1
13.59
11.88
13.72
12.3
13.57
23.24
12.07
7.32
32.9
15.89
20.64
12.98
12.55
16.72
15.95
Profit Margin (%)
15,320
7,274
9,032
9,997
10,405
12,872
15,474
10,925
7,271
8,549
9,358
9,358
10,136
6,463
13,426
2,607
156
Working Capital
6,695
12,499
10,719
10,414
13,276
13,118
16,815
14,326
22,007
21,118
18,962
18,962
16,761
16,102
13,436
15,715
13,840
LT Debt
53,288
56,363
57,486
57,033
56,268
58,210
57,722
58,239
59,035
59,230
69,031
69,031
75,152
74,353
77,857
71,710
73,143
Total Equity
10.91
10.36
8.75
7.34
7.34
8.36
7.55
6.52
7
8.08
7.72
7.95
9.33
7.62
7.69
8.4
8.26
Return on Invested Capital (%)
48.89
41.46
29.91
23.46
27.11
25.29
26.2
43.34
20.38
11.33
46.88
25.61
34.96
26.02
28.92
37.81
38.21
Return on Capital (%)
207.91
212.9
183.24
140.17
166.04
163.31
181.29
330.56
172.14
110.09
488.34
246.26
331.59
213.78
219.94
314.72
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
8,489
4,614
6,181
LT Borrowings
11,700
14,248
12,298
LT Finance Leases
1,566
1,467
1,542
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,218
1,208
1,198
Market Capitalization
97,684
101,583
99,697

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
34,042
30,952
30,164
Cash, Cash Equivalents & STI
8,906
8,467
5,544
Accounts Receivable, Net
- -
8,410
- -
Inventories
24,501
10,214
23,503
Total Current Liabilities
32,105
28,345
30,008
Payables & Accruals
23,614
9,045
23,650
ST Debt
8,489
4,614
6,181
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-7.9%
Free Cash Flow
5.82%
9.63%
22.53%
Net Income, GAAP
34.32%
-1.37%
40.52%
Sales/Revenue/Turnover
3.01%
4.58%
5.49%
Total Cash Common Dividend
2.62%
3.94%
1.45%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9,726
11,380
12,977
7,631
44,286
2025
10,606
10,735
13,170
12,205
46,716
2026
11,244
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.91
- -
2.25
0.4
4.44
2025
1.52
- -
- -
-0.66
6.4
2026
1.34
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
3.76
2025
- -
- -
- -
- -
3.91
2026
- -
- -
- -
- -
- -
Similar Companies
Tdspharm (464280.KQ)
GlaxoSmithKline plc (GSK.SW)
Virbac S.A. (VRBCF)
Roche Holding AG (0QQ6.L)
Otsuka Holdings Co., Ltd. (4578.T)
Zoetis Inc. (ZTS)
Business
Sanofi S.A. (SNW.DE) is a French multinational biopharmaceutical company focused on the research, development, manufacturing, and marketing of prescription medicines, vaccines, and over-the-counter products across therapeutic areas including immunology, neurology, oncology, rare diseases, rare blood disorders, diabetes, cardiovascular, infectious diseases, and respiratory conditions; key products include Dupixent (dupilumab) for eczema, asthma, and chronic rhinosinusitis marketed with Regeneron, insulin therapies such as Lantus (insulin glargine), Toujeo, and Soliqua for diabetes, Aubagio (teriflunomide) and Lemtrada (alemtuzumab) for multiple sclerosis, oncology treatments like Taxotere (docetaxel) and Eloxatin (oxaliplatin), rare disease therapies including Cerezyme (imiglucerase) for Gaucher's disease and Fabrazyme (agalsidase beta) for Fabry disease via subsidiary Genzyme, and a leading global vaccines portfolio through Sanofi Pasteur encompassing influenza vaccines (Fluzone, Vaxigrip), meningococcal (Menactra), polio (Imovax Polio), and others for bacterial and viral diseases. Headquartered at 46-48 Avenue de la Grande Armée in Paris's 17th arrondissement since November 2022, the company was founded in 1973 as a subsidiary of Elf Aquitaine and operates in over 70 countries with more than 83,000 employees, serving patients, healthcare professionals, and public health systems worldwide. Recent developments include the completion of acquisitions enhancing its pipeline, such as Vicebio in December 2025 for a respiratory syncytial virus (RSV) and human metapneumovirus combination vaccine candidate utilizing Molecular Clamp technology, Blueprint Medicines in July 2025 adding expertise in systemic mastocytosis and KIT-driven diseases, Vigil Neuroscience in August 2025 for neuroscience assets, an additional $625 million commitment to Sanofi Ventures in September 2025 to accelerate biotech and digital health investments, and ongoing plans to separate its consumer healthcare division Opella.